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Summary
Prevention of osteoporosis fractures is currently possible by
implementing lifestyle changes as well as with effective treat-
ments. The role played by different agents is particularly im-
portant in reducing the risk of hip fracture, which is certainly
the most severe consequence of osteoporosis in terms of de-
teriorating quality of life for the patient, reduced life expectan-
cy and health care costs.
In order to choose an adequate treatment, therapies with well-
established efficacy should be considered. In addition, for
medical treatment success, patient adherence is essential. Re-
cently published clinical data show that risedronate 75mg, ad-
ministered monthly on two consecutive days, equivalent to
risedronate 5 mg daily in terms of BMD changes, bone
turnover markers and incidence of new vertebral fractures,
and has an equivalent safety profile. The new risedronate
75mg monthly formulation, administered on two consecutive
days, is therefore the first and only oral monthly therapy with
proven efficacy in reducing the risk of vertebral, non-vertebral
and hip fractures, and a safety profile confirmed by Phase III
trials and 8-year post-marketing experience of risedronate.
Monthly dosing may offer the advantage of improving patient
compliance and persistence on the treatment, thanks to the
less frequent administration.
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Introduction
Osteoporosis is a chronic skeletal disease, characterized by re-
duced BMD and bone micro-architecture alterations and in-
creased fracture risk (1). This pathological condition has a con-
siderable clinical and epidemiological impact on the population
all over the world. The most important clinical consequence of
osteoporosis is the hip fracture, an event that is strongly asso-
ciated with patient mortality and disability, and has economic
implications in terms of increased health care costs (2). The
choice of an adequate osteoporosis treatment should be based
on a number of fundamental characteristics, including efficacy
in reducing risk of fractures, speed of action, effects in different
skeletal sites, long term efficacy safety and tolerability. Current-
ly, bisphosphonates are the treatment of choice to control os-
teoporosis and prevent severe complications due to vertebral,
non-vertebral and hip fractures (3). Similarly to other chronic
conditions, improved treatment adherence is a priority goal. In
fact, frequency of administration has been demonstrated to af-
fect patient compliance and persistence on treatment, and
therefore treatment efficacy. Nowadays the persistence on
treatment with bisphosphonate is unacceptably low (4, 5). Per-
sistence increases by extending Bisphosphonate dosing inter-
vals (6), even though dosage is not the only factor determining
treatment compliance. Knowledge of drug efficacy and safety
profile has been demonstrated to be more important than dos-
ing frequency in patient preference and compliance to Bisphos-
phonate treatment (7, 8). Recent studies have been conducted
to demonstrate the efficacy of new therapeutic approaches
based on monthly dosing of bisphosphonates (9). 
As demonstrated by Evidence Based Medicine, Risedronate
provides risk fracture protection in all skeletal sites
In the framework of bisphosphonate treatment, there are evi-
dences on risedronate efficacy and use of this agent is includ-
ed in important national and international guidelines on osteo-
porosis treatment. As demonstrated by randomized clinical tri-
als (10-12), the efficacy of Risedronate is confirmed in terms of
vertebral and non-vertebral fracture risk reduction and in terms
of safety.
Risedronate efficacy in hip fracture risk reduction has been
demonstrated in the HIP trial (Hip Intervention Program), con-
ducted on 9,331 patients at hip fracture risk. In the group of pa-
tients with low BMD and at least one prevalent vertebral frac-
ture, risedronate has been proven to reduce hip fracture inci-
dence by 60% (p=0.003) compared with the placebo group
treated with Calcium and Vitamin D (13). 
It is worth mentioning that efficacy of Ibandronate on hip frac-
ture has not been established. Moreover, regarding the efficacy
on non-vertebral fractures, the BONE trial (oral iBandronate
Osteoporosis vertebral fracture trial in North America and Eu-
rope), conducted on about 2,000 patients, showed no statisti-
cally significant difference vs. placebo in terms of incidence of
non vertebral fracture events at 3 years after treatment with
oral Ibandronate either daily (2.5mg) or intermittently (20mg
every other day for 12 doses every three months) (14). 
Clinical trials demonstrate risedronate speed of action in reduc-
ing the risk of vertebral (15) and novertebral (16) clinical frac-
tures at 6 months.
In terms of risedronate antifracture effectiveness, the results of
randomized clinical trials are confirmed by the results of REAL
(RisedronatE and ALendronate) Observational Study conduct-
ed on health care databases. The REAL trial showed that treat-
ment of osteoporosis patients (n = 33,830) with risedronate vs
alendronate at a weekly dosage significantly reduced the inci-
dence of hip fracture events at 6 months (-46%, P = 0.02) and
at 12 months (-43%, P = 0.01) (17). 
In terms of safety and tolerability data, 7-year follow-up data of
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patients enrolled in Phase III trials show good tolerability profile
of risedronate and maintenance of antifracture efficacy profile
(18). 
New data on Risedronate 75mg monthly treatment show
equivalent efficacy as Risedronate 5 mg daily dosing
Recently has been approved, in Italy and in other European
countries, the new formulation of Risedronate 75mg on two
consecutive days each month for osteoporosis treatment. The
following data illustrate the Phase III results of a recent study
by Delmas and co-workers (19).The study design included
24-month treatment of postmenopausal women with osteo-
porosis with risedronate 75 mg.e. or 5 mg daily. It was ran-
domized, double-blind trial including over 1,200 patients re-
cruited in different international centres, aged ≥ 50 years with
lumbar BMD <-2.5 or <-2.0 with one prevalent vertebral frac-
ture. The patients were blindly randomized to risedronate
5mg daily or 75mg two consecutive days each month and
placebo for the rest of the month. Supplementation with Cal-
cium (1000mg daily) and Vitamin D (400-800 IU daily) was
prescribed. The trial was designed to assess the percent
change from baseline in lumbar (LS), total hip, trochanter and
femoral neck BMD at 6 and 12 months. The incidence of mor-
phometric vertebral fractures was assessed by X-ray mea-
surements from baseline to months 12. Biochemical markers
of bone turnover (sBAP, serum bone-specific alkaline phos-
phatase; uNTX, urinary type-1 collagen N-telopeptide) were
measured at 3, 6 and 12 months. Safety was assessed based
on adverse event incidence, clinical examination and routine
laboratory tests. 
Data at 12 months show no significant difference in terms of LS
BMD changes (Fig. 1). Bone turnover markers decreased with
both treatments at 3, 6 and 12 months (Fig. 2). Incidence of
new vertebral fractures at 12 months was the same in the two
groups (Fig. 3). Identification of clinical vertebral and non-verte-
bral fractures as adverse events was similar in the two groups.
Safety data were favourable, with good general tolerability.
There were no clinically significant differences in physical ex-
aminations or laboratory measures between treatments. Ad-
verse events were generally similar between treatments, in-
cluding GI Aes (Fig. 4).
The results of the study by Delmas et al. show equivalence of
Risedronate 75 mg on two consecutive days each month to the
5 mg daily regimen both in terms of efficacy and safety, provid-
ing the first oral monthly treatment available so far for osteo-
porosis, with a complete efficacy profile on vertebral, non-ver-
tebral and hip fractures, with the opportunity to improve patient
adherence with a less frequent dosing regimen.
As an additional confirmation of the antifracture efficacy of the
less frequent dosing regimen the groups in the risedronate 75
mg Phase III trial were compared with a historical cohort of pa-
tients in the placebo arms of VERT trials (Vertebral Efficacy of
Risedronate Therapy). In presenting the results at the 2007
Congress of the American Society for Bone and Mineral Re-
search (ASBMR), Watt and co-workers explained their alterna-
tive choice of “historical” controls by underlying that the recruit-
ment of placebo groups in new trials to confirm favourable re-
sults is limited by practical, and especially by bioethical consid-
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Figure 1 - Mean percent change in BMD of the lumbar spine, total hip, femoral neck and trochanter.
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erations (20). In the “historical” placebo group, 99 patients from
the VERT trials were included with homogeneous clinical and
demographic characteristics (age, years since menopause,
BMD and incidence of previous vertebral fractures) with re-
spect to the patients enrolled in the risedronate 75mg trial. The
same criteria were used in the recruitment of a forth group of
96 patients treated with risedronate 5mg daily in the VERT tri-
als (5mg “historical” group). Retrospective comparison of data
after 12 months of treatment confirmed that the risk of new ver-
tebral fractures in the risedronate 75mg group was less than
79% vs the “historical” placebo group (p = 0.016), the reduction
being similar to the VERT MN and NA trials (61 and 65%, re-
spectively) on active treatment with risedronate 5 mg daily (Fig.
5). Moreover, the incidence of new vertebral fractures (internal
validation test) was similar in the 3 groups in active treatment.
Therefore, monthly risedronate dosing leads to considerable
BMD improvement in patients with postmenopausal osteoporo-
sis, similarly to risedronate 5mg, with a similar antifracture effi-
cacy as the conventional daily treatment and a 79% reduction
in the risk of new vertebral fractures in the first year of treat-
ment vs the historical placebo group. 
Risedronate 75mg is the monthly treatment with the 
broadest antifracture efficacy
The increasing amount of evidence available has enabled the
US (FDA) and European Regulatory Authorities to approve the
monthly risedronate 75 mg on two consecutive days each
month, with proven antifracture efficacy and safety similar to
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Figure 2 - Mean percent change from baseline in bone turnover markers.
Figure 3 - Incidence of new vertebral fractures at 12 months.
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Selected Adverse Event Incidence at Month 12
Adverse events RIS 5 mg RIS 75 mg
(N = 613) (N = 616)
Serious TEAEs 4.7% (29) 7.5% (46)
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daily 5 mg risedronate. Risedronate 75mg provides a new and
effective option for postmenopausal osteoporosis treatment
and prevention of fractures offering patients the option of a less
frequent dosing regimen and the opportunity to improve adher-
ence and consequently obtain optimal long-term control of os-
teoporosis. Moreover, risedronate efficacy data at 6 months of
treatment (15, 16) provide a peculiar efficacy profile to meet
the growing health care needs due to frequent and burden-
some fragility fractures.
Both new clinical trials and observational studies have con-
firmed that risedronate provides a convenient therapeutic op-
tion for osteoporosis, being the only drug available for oral
monthly administration in its category, with proven antifracture
efficacy on vertebral and non-vertebral fractures. 
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Figure 5 - Risedronate 75 mg Matched Historical Control Study to as-
sess Anti-Fracture Efficacy.
Incidence of New Vertebral Fractures in all 4 groups
(1 year data)
Placebo 75 mg 5 mg 5 mg
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Historical Historical
(N=99) (N=616) (N=96) (N=613)
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